Exclusivity rights, such as patents, data exclusivity and other forms of market exclusivities, have been used as an incentive to promote pharmaceutical innovation by granting temporary monopolies over innovations. However, they have often resulted in high medicine prices and have not necessarily led to the health-needed innovations they were meant to incentivize. During this webinar, Julia Paranhos will present a study on the costs of patent term extensions to the public health system in Brazil and implications for ongoing policy and judicial discussions. She will discuss a case in the Brazilian Supreme Court challenging the constitutionality of such extensions in light of the public interest. Ellen ‘t Hoen will present a study on how market exclusivities have affected access to medicines and innovation in Europe. She will offer recommendations for changes to current policies on Supplementary Protection Certificates, Data Exclusivity, and Orphan Medicinal Product regulations.
Speakers
- Julia Paranhos, Associate Professor, Economics Institute of the Federal University of Rio de Janeiro
- Ellen ‘t Hoen, Director, Medicines Law & Policy
- Moderated by Suerie Moon, Co-Director, Global Health Centre
Event Materials
- Paranhos J, Mercadante E, Hasenclever L, O custo para o SUS da extensão da vigência de patentes de medicamentos. Cadernos de Saúde Pública, forthcoming. Executive summary in English: Public health system increasing costs due to the extension of drug patents terms
- ‘t Hoen Ellen et al. (2019) EU Review of Pharmaceutical Incentives: Suggestions for Change. Medicines Law and Policy.
- Presentation by Julia Paranhos
- Presentation by Ellen 't Hoen
- Q&A with the Participants
